← Back to home

Non-surgical management;DMMR/msi-H gastric cancer;neoadjuvant immunotherapy

Clinical trials for Non-surgical management;DMMR/msi-H gastric cancer;neoadjuvant immunotherapy explained in plain language.

Never miss a new study

Get alerted when new Non-surgical management;DMMR/msi-H gastric cancer;neoadjuvant immunotherapy trials appear

Sign up with your email to follow new studies for Non-surgical management;DMMR/msi-H gastric cancer;neoadjuvant immunotherapy, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

Could immunotherapy let some stomach cancer patients skip surgery?

Disease control By invitation only

This study looks at whether a combination of two immunotherapy drugs (Durvalumab and Tremelimumab) can control advanced stomach cancers with specific genetic features (dMMR/MSI-H) well enough to avoid surgery. The trial enrolls 12 adults who would normally need chemotherapy and s…

Matched conditions: NON-SURGICAL MANAGEMENT;DMMR/MSI-H GASTRIC CANCER;NEOADJUVANT IMMUNOTHERAPY

Sponsor: Yong Zhou • Aim: Disease control

Last updated Aug 21, 2026 00:00 UTC

Non-surgical management;DMMR/msi-H gastric cancer;neoadjuvant immunotherapy

Get alerted when new Non-surgical management;DMMR/msi-H gastric cancer;neoadjuvant immunotherapy trials appear

Could immunotherapy let some stomach cancer patients skip surgery?